Clinical and spirometric alterations in Duchenne muscular dystrophy

被引:0
|
作者
Andrada, LE [1 ]
DeVito, EL [1 ]
机构
[1] UNIV BUENOS AIRES, FAC MED, INST INVEST MED ALFREDO LANARI, RA-1053 BUENOS AIRES, DF, ARGENTINA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In 36 patients with Duchenne muscular dystrophy we studied the growth pattern, the type and severity of the spirometric abnormalities, the evolution of the Motor Functional Class (MFC), the infectious complications and treatments. Their age ranged from 6 to 19 years and the MFC was from 1 to 9. Regarding height, up to 12 years we verified a slope of 5.69 +/- 0.58 cm/year (r 0.872 p < 0.001) and a posterior detention was observed. Of the 36 patients, 24 were below the percentile 5. The restrictive disorder prevailed. The forced Vital capacity (FVC) expressed in % of the theoretical Value showed a lineal fall with age, with a negative correlation (r 0.51, p < 0.01) of - 3.5 +/- 0.83%/year. The deterioration of the MFC was marked starting from 6 years; with a slope of 0.84 +/- 0,14 points between 6 to 12 years (r 0.73 p x 0.001). Up to 14 years, the slope was 0.212 +/- 0.084 (r 0.49, p < 0,05). Patients older than 14 years had reached a greater CFM of 7; starting from this MFC a progressive fall of the VC was observed with a slope of - 15.29 +/- 3.39% of CVF/CF (r 0.56, p < 0.001). Nine patients with respiratory infections were documented. Four were pneumonia and 3 of them required mechanical ventilation and died. Only 50% of the patients accepted rehabilitating treatment. Four patients accepted surgery of the alterations of the feet while the patients with deformation of the column underwent spinal stabilization.
引用
收藏
页码:463 / 471
页数:9
相关论文
共 50 条
  • [41] Epilepsy in Duchenne muscular dystrophy
    Gomez, J. Armijo
    Liz, M.
    Ortez, C.
    Dominguez-Carral, J.
    Exposito-Escudero, J.
    Carrera-Garcia, L.
    Natera De Benito, D.
    Nascimento, A.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S177 - S177
  • [42] DUCHENNE MUSCULAR-DYSTROPHY
    PERRY, SV
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1984, 12 (03) : 362 - 365
  • [43] DUCHENNE MUSCULAR-DYSTROPHY
    LINTER, SPK
    BRITISH MEDICAL JOURNAL, 1983, 287 (6402): : 1381 - 1381
  • [44] Noncompaction in Duchenne Muscular Dystrophy
    Finsterer, Josef
    Zarrouk-Mahjoub, Sinda
    INTERNAL MEDICINE, 2016, 55 (09) : 1241 - 1241
  • [45] Duchenne Muscular Dystrophy.
    Mielnik-Blaszczak, M
    JOURNAL OF DENTAL RESEARCH, 2001, 80 (04) : 1218 - 1218
  • [46] DUCHENNE MUSCULAR-DYSTROPHY
    EMERY, AEH
    CLINICAL GENETICS, 1983, 23 (03) : 198 - 198
  • [47] DUCHENNE MUSCULAR-DYSTROPHY
    SADJADPOUR, K
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1975, 234 (04): : 382 - 382
  • [48] Theragnosis for Duchenne Muscular Dystrophy
    Luce, Leonela
    Carcione, Micaela
    Mazzanti, Chiara
    Buonfiglio, Paula I.
    Dalamon, Viviana
    Mesa, Lilia
    Dubrovsky, Alberto
    Corderi, Jose
    Giliberto, Florencia
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [49] SLEEP IN DUCHENNE MUSCULAR DYSTROPHY
    Low, Dominique
    Ghosh, Partha
    SLEEP, 2024, 47
  • [50] Nanotherapy for Duchenne muscular dystrophy
    Nance, Michael E.
    Hakim, Chady H.
    Yang, N. Nora
    Duan, Dongsheng
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2018, 10 (02)